CN1146362A - Capsule for anti hepatitis B - Google Patents
Capsule for anti hepatitis B Download PDFInfo
- Publication number
- CN1146362A CN1146362A CN 96118766 CN96118766A CN1146362A CN 1146362 A CN1146362 A CN 1146362A CN 96118766 CN96118766 CN 96118766 CN 96118766 A CN96118766 A CN 96118766A CN 1146362 A CN1146362 A CN 1146362A
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- capsule
- radix
- herba
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invented capsule is composed of root of Chinese thorowax, root of red-rooted salvia, curcuma root, red peony root, white peony root, bushy knotweed, capillary artemisia, hedyotis etc. 20 traditional Chinese medicinal herbs and is made up through the process of washing separately, drying, crushing, grinding into fine powder, sieving with 80-120 mesh sieve, mixing thoroughly the sieved fine powder, bactericidal treatment, and capsulizing under the aseptic condition. The advantages are high rate of antigen turning to negative, without toxic side effect to humanbody and capable of taking for a long period of time.
Description
The present invention relates to a kind of medicine for the treatment of hepatitis B, especially relating to a kind of is the anti-hepatitis B capsule of feedstock production with the vegetable Chinese herbal medicine.
Hepatitis B is one of the world's three big pertinacious diseases of serious harm human health, is only second to AIDS and cancer, and China is according to relevant investigation in 1993, and the infection rate of hepatitis B has population more than 700,000,000 to infect up to 61% through calculating approximately, and increases year by year.
The easy chronicity of hepatitis B, the course of disease is long, and touching difficulty more easily develops into liver cirrhosis, hepatocarcinoma.Its case fatality rate height.Chinese and western medicine hepatopathy bound pair does not still have breakthrough in the treatment of hepatitis B both at home and abroad at present, especially for the inhibition and the removing of chronic HBV, become the great difficult problem in the treatment, up to now, also do not have a kind of generally acknowledged curative effect height, the effect of paying less, antigen negative conversion rate height, good reproducibility, effective comprehensive high curative effect medicine.
The key of thoroughly curing hepatitis B is to suppress duplicating of hepatitis B virus, ends its persistent infection, reaches disease and cause of disease detection index and improves synchronously, and this is the focus difficult problem of the urgent tackling key problem of Chinese and western medicine hepatopathy circle urgent need just.The Chinese and western medicine medicine of treatment hepatitis B has following thorny problem both at home and abroad at present:
1, Western medicine antiviral, regulate immune class medicine: (1) does anti-plain, and (2) anti-hepatitis B immune ribonucleic acid, (3) vidarabine, (4) acyclovir (acyclovir), (5) interleukin II (IL2) activate self mononuclearcell feedback therapy.This type of drug price costliness, administration time is long, and side effect is big, and the antigen negative conversion rate is low, very easily knock-on after the drug withdrawal, long-term prescription, general patient is difficult to bear, and is difficult for promoting.
2, the Chinese patent medicine of various treatment hepatitis ies, as manyzoned polypore gantai, liver must be answered, MIEAOLING, sharp liver is grand, hepatitis B detoxifying capsule, hepatitis B strengthening capsule is used to regulate immune medicines such as polyporusum bellatus, pass through observation on Clinical Application, have only part patient clinical symptoms slightly to be improved, and most important defective is for the inhibition hepatitis B replication, curative effect is very little.
3, hepatitis B pathology mechanism is complicated, and the course of disease is long, and touching difficulty is taken decoction for a long time, and the flavour of a drug bitterness easily causes drug induced gastritis, and the patient is difficult to accept.
Disclose a kind of " pellet for detoxication of hepatitis B and preparation method thereof " July 19 nineteen ninety-five, (application number: 94108841), its prescription and content, (unit: g) Radix Scutellariae 5-15.0, Radix Gentianae 5-15.0, Fructus Gardeniae 5-15.0, Herba Hedyotidis Diffusae (two leaves
) 5-15.0, Flos Lonicerae 5-15.0, Fructus Forsythiae 5-15.0, Herba Taraxaci 5-15.0, Herba Violae 5-15.0, Herba Scutellariae indicae 5-15.0, Radix Rehmanniae 5-15.0, Radix Scrophulariae 5-15.0, Cortex Moutan 5-15.0, Radix Salviae Miltiorrhizae 7-17.0, Radix Paeoniae Rubra 5-15.0, smoke 5-15.0, careless Moschus 5-15.0, mother-in-law Artemisia 5-15.0, Herba Antenoronis Neofiliformis 5-15.0, SHENCAO 10-20.0, Radix Paeoniae Alba 5-15.0, Fructus Schisandrae Chinensis 5-15.0, Cornu Bubali 5-15.0.This pellet focuses on the Australia of going out of detoxifying, and can prevent acute.The patient with severe symptoms transfers to chronic and worsens the patient, and has overcome and treat the drawback that hepatitis B medicine is easily upset one's stomach in the past, the unique curative effect that reaches not only toxin expelling but also be good for the stomach.But the pharmaceutical formulation principle of this product focuses on clearing away heat,cooling blood and removing toxin, the immunity of fundamentally having ignored kidney and be human body this, the root of yang-energy, YANG of five ZANG-organs, non-this can not be sent out, this pellet is crossed and is used the clearing away heat,cooling blood and removing toxin medicine, easily holds back and hinders the body yang-energy, makes body's immunity be in tolerance status, cause virus replication active, the more important thing is that this product takes through chronic hepatitis B patient, its feedback information shows that curative effect is low, the course of treatment is long, especially duplicate, regulate, excite, improve aspect the immunologic function suppressing the hepatitis B virus breeding, do not have definite curative effect, thus with a low credibility.
On November 22nd, 95, Chinese patent discloses " Chinese medicine preparation of a kind of prevention and treatment hepatitis B ", (application number: 951038834) this product has been ignored hepatitis B and has easily been caused depression of liver-QI, meridians stop up stagnate obstructed, liver blood stasis, hepatic insufficiency.The normal catharsis of liver is that normal performance of immunologic function and meridians are unobstructed, the basic assurance that each function is coordinated.Though this product effective percentage can reach 98%, the antigen negative conversion rate is low, and HBsAg 33.7%, and HBeAg 48.8%, and its clinical observation shows that this medicine duplicates in the breeding of inhibition hepatitis B virus, ends its persistent infection aspect, does not have obviously and breaks through.
The object of the present invention is to provide a kind of anti-hepatitis B capsule, it has soothing the liver the kidney invigorating, the promoting blood circulation and detoxication dampness removing, suppressing the hepatitis B virus breeding duplicates, regulate, excite, the human body immunity improving function, enzyme, promoting the function of the gallbladder to alleviate jaundice fall, stop hepatic fibrosis, recover liver function, reach disease and objective detection index obtain to be improved as synchronously one, better, effective, nontoxic pair of effect of repeatability, cheap, save medical material, making simply, antigen negative conversion rate height, the comprehensive high curative effect medicine of anti-hepatitis B being convenient to promote.
Technical solution of the present invention is based on the cause of disease of hepatitis B and pathogeny and Therapeutic Principle's understanding, the cause of disease of hepatitis B is " epidemic disease poison " but not " damp and hot ", and damp and hot, blood stasis is that hepatitis B virus duplicates active pathological product in vivo.It is chronic hepatitis B important pathological basis that stagnation of liver-QI is suffered from a deficiency of the kidney.Its pathological change is the stagnation of QI due to depression of the liver blood stasis then, suffer from a deficiency of the kidney, the epidemic disease poison not to the greatest extent, according to blood stored in the liver, kidney storing essence, essence and blood is changed mutually, and yi and Kui are derived from the same origin, kidney are basis of human immunity, the root of yang-energy, the normal catharsis of liver are the unobstructed and normal basic assurances of bringing into play of body's immunity of meridians, and the cause of disease is the mechanism of epidemic disease poison; With reference to modern pharmacological research, therefrom filter out and have soothing the liver the kidney invigorating, promoting blood circulation and detoxication, the dampness removing characteristics are arranged again, doublely can kill and suppress medicine that hepatitis B virus breeding duplicates as target therapeutic agent, the soothing the liver liver catharsis function that makes is normal, each function is transferred smooth, and immunologic function is normally brought into play.The kidney invigorating can be regulated, excite, the human body immunity improving function, invigorating blood circulation to promote blood circulation in the liver, quicken the hepatocyte metabolism, promote hepatocyte to repair, the disease-resistant detoxification ability of enhance hepatocyte stops hepatic fibrosis, be beneficial to remove blood stasis epidemic disease poison, detoxifcation can directly be killed and suppress the breeding of hepatitis B virus and duplicate, and dampness removing can destroy the living environment of hepatitis B virus effectively, weakens its virulence and fertility.
Its concrete scheme is:
(1) pharmaceutical formulation of anti-hepatitis B capsule and proportioning are as follows: by weight
Radix Bupleuri 10-15.0: Radix Salviae Miltiorrhizae 15-20.0: Radix Curcumae 15-20.0: Radix Paeoniae Rubra 15-20.0: Radix Paeoniae Alba 10-15.0: Rhizoma Polygoni Cuspidati 20-30.0: Herba Artemisiae Scopariae 30-40.0: Herba Hedyotidis Diffusae 20-30.0: Rhizoma Smilacis Glabrae 20-30.0: Fructus Forsythiae 20-30.0: Caulis Akebiae 10-15.0: Herba Lophatheri 10-15.0: Lysimachia christinae Hance 20-30.0: cyrtomium fortunei 20-30.0: Fructus Crataegi 15-30.0: Fructus Schisandrae Chinensis 10-20.0: Radix Astragali 30-60.0: crust halberd 10-20.0: parasitic 20-30.0: Radix Glycyrrhizae 6-10.0
(2) with above-mentioned formulation of drug, respectively after cleaning, drying, pulverizing, be ground into fine powder, cross the 80-120 mesh sieve, with the abundant mixing of gained medicated powder, sterilization, promptly make the anti-hepatitis B capsule that claims in the present invention after under gnotobasis, being respectively charged into capsule, the present invention is called anti-hepatitis B I capsule, also formulation method is made water pill routinely, close ball or tablet.
The prescription of proportioning also can add in above-mentioned (1): Semen Cuscutae 15-20.0: behind the Herba Epimedii 15-30.0, made medicine is called anti-hepatitis B II capsule in the present invention.
Clinical drug application result of the present invention shows following advantage:
1, medicine material of the present invention is pure vegetable Chinese herbal medicine, to nontoxic pair of effect of human body, can take for a long time, and safely, be easy to accept.
2, medicine of the present invention has been saved medical material through grinding and processing, has avoided losing of effective ingredient, has strengthened medicine and solvent contact surface, make the medicine active ingredient fully leach absorption, take, easy to carry, curative effect shows Millefolium, reduce expenses, need not decoct, be suitable for suitability for industrialized production.
3, medicine of the present invention can replace expensive Western medicine antiviral agents and alt-reducing and liver-protecting medicine, (interferon, 1,000,000 units, 138 yuan every) take separately, can reach antiviral, excite the human body immunity improving function, fall enzyme, promoting the function of the gallbladder to alleviate jaundice, recovery liver function, stop the comprehensive therapeutic effect of hepatic fibrosis.
4, antigen negative conversion rate height, HBsAg negative conversion rate 73.3%, effective percentage 93.3%, HBeAg negative conversion rate 83.7%, effective percentage 91.8%, anti--HBC negative conversion rate 82.1%, anti--HBe negative conversion rate 100%, PHSA-R negative conversion rate 70%, clinical basic cure rate (always) 88.3%, total effective rate 98.3%.
5, for showing the therapeutic effect of medicine of the present invention to chronic hepatitis B, elite selecting through various Chinese and Western antiviral, regulate immunity, after the treatment of alt-reducing and liver-protecting medicine, the 60 routine patients that the serum hepatitis B virus sign continues not turn out cloudy, all measure the serum hepatitis B virus sign before the treatment, all the patient has more than one positive, measure liver function simultaneously, during the These parameters treatment and behind the stopped treatment, the every three months check once, during the treatment, all the patient withdraws antiviral Western medicine and the existing Chinese patent medicine and the liver protecting and ALT lowering medicine of all treatment hepatitis ies, " viral hepatitis traditional Chinese medical science curative effect determinate standard " that curative effect determinate standard is formulated by in December, 1991 China national tcm internal medicine hepatopathy Professional Committee Tianjin meeting judged, the each patient all treated 3-6 month continuously, surpass some cases course of treatment half a year, three months course of treatment, observe 1-4 the course of treatment continuously altogether.
Therapeutic outcome: anti-hepatitis B capsule sees table 1 for details to the influence of chronic HBV mark, and anti-hepatitis B capsule sees table 2 for details to the clinical therapeutic efficacy of chronic hepatitis B.
Table 1, anti-hepatitis B capsule is to the influence of hepatitis B mark
| ????????????????HBsAg | ??HBeAg | Anti--HBC | ??PHSAR | Anti--HBe |
| Positive example several 60 before the treatment | ??37 | ??56 | ??20 | ??12 |
| Turn out cloudy routine several 44 (73.3) after the treatment | ??31(83.7) | ??46(82.1) | ??14(70.0) | ??12(100.0 |
Table 2, anti-hepatitis B capsule is to the therapeutic effect of chronic hepatitis B
| Typing | The example number | Clinical basic smelting is example (%) more | Produce effects example % | Routine % takes a turn for the better | Invalid routine % |
| Chronic persistent hepatitis B | ??30 | ???29(96.7) | ????1(3.3) | ????0 | ????0 |
| Chronic active hepatitis B | ??30 | ???24(80) | ????3(10.0) | ????2(6.7) | ????1(3.3) |
For the influence of liver function, before this group patient treatment, serum glutamic pyruvic transminase rising person 42 examples, treatment back full recovery normal (＜40u/L, reitman-frankel method), icteric index is greater than 17.1umol/L person's 23 examples before the treatment, and treatment back full recovery is normal.
Embodiment 1:
Anti-hepatitis B I capsule takes by weighing raw material (unit: g) by following proportioning
One two three
Radix Bupleuri 10.0 12.0 15.0
Radix Salviae Miltiorrhizae 15.0 18.0 20.0
Radix Curcumae 15.0 18.0 20.0
Radix Paeoniae Rubra 15.0 18.0 20.0
The Radix Paeoniae Alba 10.0 12.0 15.0
Rhizoma Polygoni Cuspidati 20.0 24.0 30.0
Herba Artemisiae Scopariae 30.0 35.0 40.0 Herba Hedyotidis Diffusaes 20.0 24.0 30.0
Rhizoma Smilacis Glabrae 20.0 24.0 30.0
Fructus Forsythiae 20.0 24.0 30.0
Caulis Akebiae 10.0 12.0 15.0
Herba Lophatheri 10.0 12.0 15.0
Lysimachia christinae Hance 20.0 24.0 30.0
Fructus Crataegi 20.0 24.0 30.0
Cyrtomium fortunei 20.0 24.0 30.0
Fructus Schisandrae Chinensis 10.0 15.0 20.0
The Radix Astragali 30.0 45.0 60.0
Crust halberd 10.0 15.0 20.0
Parasitic 20.0 24.0 30.0
Radix Glycyrrhizae 6.0 8.0 10.0 embodiment 2:
Anti-hepatitis B II capsule takes by weighing raw material (unit: g) by following proportioning
One two three
Radix Bupleuri 10.0 12.0 15.0
Radix Salviae Miltiorrhizae 15.0 18.0 20.0
Radix Curcumae 15.0 18.0 20.0
Radix Paeoniae Rubra 15.0 18.0 20.0
The Radix Paeoniae Alba 10.0 12.0 15.0
Rhizoma Polygoni Cuspidati 20.0 24.0 30.0
Herba Artemisiae Scopariae 30.0 35.0 40.0 Herba Hedyotidis Diffusaes 20.0 24.0 30.0
Rhizoma Smilacis Glabrae 20.0 24.0 30.0
Fructus Forsythiae 20.0 24.0 30.0
Caulis Akebiae 10.0 12.0 15.0
Herba Lophatheri 10.0 12.0 15.0
Lysimachia christinae Hance 20.0 24.0 30.0
Fructus Crataegi 20.0 24.0 30.0
Cyrtomium fortunei 20.0 24.0 30.0
Fructus Schisandrae Chinensis 10.0 15.0 20.0
The Radix Astragali 30.0 45.0 60.0
Crust halberd 10.0 15.0 20.0
Parasitic 20.0 24.0 30.0
Semen Cuscutae 15.0 18.0 20.0
Herba Epimedii 15.0 20.0 24.0
Radix Glycyrrhizae 6.0 8.0 10.0
Anti-hepatitis B capsule of the present invention cures mainly chronic persistent hepatitis B, chronic active hepatitis B, hepatitis b virus carrier, acute hepatitis B.Wherein anti-hepatitis B I capsule is applicable to abnormal liver function (that is: glutamate pyruvate transaminase, bilirubin raise), and clinical manifestation is, xerostomia hardship, side of body distending pain, yellow urine, weak limb are soft, poor appetite, yellow and thin fur or BOHUANG is greasy, people with thready and slippery pulse.Anti-hepatitis B II capsule is applicable to that liver function substantially normally or only shows as glutamate pyruvate transaminase and slightly raises, and clinical manifestation is unable, the lower limb of general fatigue
Bloated poor appetite of soft, the side of body or right side of body dull pain etc.Acute hepatitis B, bilirubin rising and glutamate pyruvate transaminase obviously rising person are avoided clothes.
Instructions of taking: 6-8 gram/time, day clothes three times, ante cibum warm water delivery service.
Claims (2)
1, a kind of anti-hepatitis B capsule is characterized in that:
(1), selected pharmaceutical formulation and proportioning thereof are as follows: by weight
Radix Bupleuri 10-15.0: Radix Salviae Miltiorrhizae 15-20.0: Radix Curcumae 15-20.0: Radix Paeoniae Rubra 15-20.0: Radix Paeoniae Alba 10-15.0: Rhizoma Polygoni Cuspidati 20-30.0: Herba Artemisiae Scopariae 30-40.0: Herba Hedyotidis Diffusae 20-30.0: Rhizoma Smilacis Glabrae 20-30.0: Fructus Forsythiae 20-30.0: Caulis Akebiae 10-15.0: Herba Lophatheri 10-15.0: Lysimachia christinae Hance 20-30.0: cyrtomium fortunei 20-30.0: Fructus Crataegi 15-30.0: Fructus Schisandrae Chinensis 10-20.0: Radix Astragali 30-60.0: crust halberd 10-20.0: parasitic 20-30.0: Radix Glycyrrhizae 6-10.0
(2), with above-mentioned formulation of drug, respectively through clean, dry, pulverize after, be ground into powder, cross the 80-120 mesh sieve, with the abundant mixing of gained medicated powder, sterilization, promptly make the anti-hepatitis B capsule that claims among the present invention after under gnotobasis, being respectively charged into capsule.
2, a kind of anti-hepatitis B capsule described in claim 1 is characterized in that: also have in the described pharmaceutical formulation: Semen Cuscutae 15-20.0: Herba Epimedii 15-30.0.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96118766A CN1059104C (en) | 1996-09-27 | 1996-09-27 | Capsule for anti hepatitis B |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96118766A CN1059104C (en) | 1996-09-27 | 1996-09-27 | Capsule for anti hepatitis B |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1146362A true CN1146362A (en) | 1997-04-02 |
| CN1059104C CN1059104C (en) | 2000-12-06 |
Family
ID=5125332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN96118766A Expired - Fee Related CN1059104C (en) | 1996-09-27 | 1996-09-27 | Capsule for anti hepatitis B |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1059104C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100434094C (en) * | 2004-12-24 | 2008-11-19 | 同济大学 | Medication for curing hepatic fibrosis and hepatic cirrhosis, and prepartion method |
| CN103191218A (en) * | 2013-04-30 | 2013-07-10 | 杨春成 | Traditional Chinese medicine for treating viral hepatitis |
| CN104547764A (en) * | 2014-12-20 | 2015-04-29 | 何庆军 | Medicine for recovering liver functions and preparation method thereof |
| CN104840574A (en) * | 2015-05-27 | 2015-08-19 | 湖南中医药大学 | Traditional Chinese medicine composition for treating liver diseases and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1943753B (en) * | 2005-10-08 | 2011-04-13 | 周小明 | A Chinese traditional medicinal composition for treatment of hepatitis B and its preparation method |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1078897A (en) * | 1993-01-03 | 1993-12-01 | 于灵惠 | " hepatitis B health " Chinese medicine preparation and preparation technology thereof |
| CN1078902A (en) * | 1993-05-03 | 1993-12-01 | 周玉 | Treatment hepatitis B Chinese medicine |
-
1996
- 1996-09-27 CN CN96118766A patent/CN1059104C/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100434094C (en) * | 2004-12-24 | 2008-11-19 | 同济大学 | Medication for curing hepatic fibrosis and hepatic cirrhosis, and prepartion method |
| CN103191218A (en) * | 2013-04-30 | 2013-07-10 | 杨春成 | Traditional Chinese medicine for treating viral hepatitis |
| CN103191218B (en) * | 2013-04-30 | 2014-08-13 | 杨春成 | Traditional Chinese medicine for treating viral hepatitis |
| CN104547764A (en) * | 2014-12-20 | 2015-04-29 | 何庆军 | Medicine for recovering liver functions and preparation method thereof |
| CN104840574A (en) * | 2015-05-27 | 2015-08-19 | 湖南中医药大学 | Traditional Chinese medicine composition for treating liver diseases and preparation method thereof |
| CN104840574B (en) * | 2015-05-27 | 2017-11-28 | 湖南中医药大学 | A kind of Chinese medicine composition for treating hepatopathy and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1059104C (en) | 2000-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1692939A (en) | Traditional Chinese medicine pill for treating hepatitis B, and its prepn. method | |
| CN1562160A (en) | Composite medicine for treating hepatitis B complication | |
| CN101041033A (en) | Chinese medicine for treating hepatitis B | |
| CN1059104C (en) | Capsule for anti hepatitis B | |
| CN1066628C (en) | Medicine for chronic hepatitis B and its preparation | |
| CN1150926C (en) | Medicine for treating hepatism | |
| CN105687579A (en) | Traditional Chinese medicine composition for treating bronchial asthma | |
| CN104940418A (en) | Pure traditional Chinese medicine pills for treating hepatitis and preparation method thereof | |
| CN1939498A (en) | Chinese-medicinal preparation for treating psoriasis | |
| CN114699498A (en) | Pharmaceutical composition for resisting chronic hepatitis B and application thereof | |
| CN1686210A (en) | Traditional Chinese medicinal preparation for treating hepatitis B | |
| CN1318378A (en) | Heat syndrome treating Chinese medicine | |
| CN102813855A (en) | Chinese herbal preparation used for treating chronic viral hepatitis type b and taking method thereof | |
| CN1070378C (en) | Medicine for curing hepatitis B | |
| CN1136939A (en) | Chinese drugs for curing hepatitis B | |
| CN1208083C (en) | A Chinese medicinal composition for treating visceral inflammation, toxin and endocrine disturbance | |
| CN1323709C (en) | Traditional Chinese medicine decoction for treating gynecological diseases | |
| CN1190229C (en) | Medicine for curing hepatitis B | |
| CN1130529A (en) | Aizikangfuning-Chinese patent drug for treating AIDS and preparing process thereof | |
| CN1159057C (en) | Medicine for treating hepatitis, and preparing process thereof | |
| CN1352966A (en) | Medicine for treating tracheitis and asthma | |
| CN1310669C (en) | Medicine composition for treating chronic hepatitis and its prepn | |
| CN1242768C (en) | Hepatitis treating medicine and its preparing process | |
| CN1086949C (en) | Chinese medicine for hepatitis B and its preparation | |
| CN1128634C (en) | Hepatitis B recuperating medicine granule |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |